N
HOWL icon

Nuveen’s Werewolf Therapeutics HOWL Stock Holding History

Nuveen’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-73,370
Closed -$71.3K – 3320
2025
Q1 		$71.3K Hold
73,370
– – ﹤0.01% 3243
2024
Q4 		$109K Hold
73,370
– – ﹤0.01% 3281
2024
Q3 		$156K Buy
73,370
+21,322
+41% +$48.5K ﹤0.01% 3262
2024
Q2 		$127K Buy
+52,048
New +$250K ﹤0.01% 3291
2022
Q2 		– Sell
-36,879
Closed -$731K – 3360
2022
Q1 		$731K Hold
36,879
– – ﹤0.01% 2914
2021
Q4 		$731K Buy
36,879
+16,916
+85% +$255K ﹤0.01% 2960
2021
Q3 		$396K Buy
19,963
+7,962
+66% +$136K ﹤0.01% 3210
2021
Q2 		$209K Buy
+12,001
New +$164K ﹤0.01% 3244

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Nuveen's HOWL Position: Q2 2025 in Review

Nuveen sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 73,370 shares — an estimated $71.3K sold.

Nuveen first reported a position in HOWL in Q2 2021 and held it in 8 quarters. The position peaked at $731K in Q1 2022. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Nuveen reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 73,370 Werewolf Therapeutics shares in Q2 2025, an estimated $71.3K.
  • Nuveen first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 8 quarters.
  • Nuveen's Werewolf Therapeutics position peaked at $731K in Q1 2022.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.